AXSM Axsome Therapeutics
- 87.320
- +2.710+3.20%
- 87.800
- +0.480+0.55%
Axsome Therapeutics News
Alzheimer's Drug Study Yields Mixed Results. Wall Street Still Likes Axsome
Axsome Therapeutics Price Target Cut to $122.00/Share From $124.00 by Mizuho
Axsome Therapeutics Is Maintained at Outperform by Mizuho
Express News | Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $122
Axsome Therapeutics Mixed Alzheimer's Disease Agitation Data Disappoints but Approvability Seen Likely, Mizuho Says
Leerink Partners Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $110
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $124
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $116 to $180
Truist Says 'Aggressive' Buying Axsome Therapeutics After AXS-05 ADA Data
Express News | HC Wainwright & Co. Reiterates Buy on Axsome Therapeuticsto Buy
Buy Rating for Axsome Therapeutics: Promising AXS-05 Efficacy in Alzheimer's Agitation
RBC Capital Adjusts Price Target on Axsome Therapeutics to $138 From $132, Keeps Outperform Rating
Express News | Axsome Therapeutics Inc : Needham Raises Target Price to $133 From $130
Positive Outlook for Axsome Therapeutics: AXS-05 Advances Despite Setbacks
Axsome Therapeutics Stock Slips 12% On Mixed Results On Alzheimer's Study
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts
Analysts' Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM) and Ascendis Pharma (ASND)
No Data